Geriatric Psychopharmacology: Why Does Age Matter?

REFERENCES

• Popkin MK, Callies AL, Mackenzie TB. The outcome of anti- depressant use in the medically ill. Arch Gen Psychiatry 1985;42:1160–3.
   Google Scholar
• Katz IR, Simpson GM, Curlik SM, Parmelee PA, Muhly C. Pharmacologic treatment of major depression for elderly pa- tients in residential care settings. J Clin Psychiatry 1990; 51(suppl):41–7.
   Google Scholar
• Zubenko GS, Mulsant BH, Rifai AH, Sweet RA, Pasternak RE, Marino LJ Jr, et al. Impact of acute psychiatric inpatient treatment on major depression in late life and prediction of response. Am J Psychiatry 1994;151:987–94.
   PubMed Web of Science ®Google Scholar
• Baum C, Kennedy DL, Knapp DE, Juergens JP, Faich GA. Prescription drug use in 1984 and changes over time. Med Care 1988;26:105–14.
   Google Scholar
• Chrischilles EA, Foley DJ, Wallace RB, Lemke JH, Semla TP, Hanlon JT, et al. Use of medications by persons 65 and over: data from the established populations for epidemiologic stud- ies of the elderly. J Gerontol Med Sci 1992;47:M137–44.
   Google Scholar
• Helling DK, Lemke JH, Semla TP, Wallace RB, Lipson DP, Cornoni-Huntley J. Medication use characteristics in the el- derly: the Iowa 65+ Rural Health Study. J Am Geriatr Soc 1987;35:4–12.
   PubMed Web of Science ®Google Scholar
• Lamy PP. Prescribing for the elderly. Littleton, Massachu- setts: PSG, 1980.
   Google Scholar
• Zubenko GS, Marino LJ Jr, Sweet RA, Rifai AH, Mulsant BH, Pasternak RE. Medical comorbidity in elderly psychiat- ric inpatients. Biol Psychiatry 1997;41:724–36.
   Google Scholar
• Sonies BC. Oropharyngeal dysphagia in the elderly. Clin Ge- riatr Med 1992;8:569–77.
   PubMedGoogle Scholar
• Jost WH. Gastrointestinal motility problems in patients with Parkinson’s disease: effects of antiparkinsonian treatment and guidelines for management. Drugs Aging 1997;10:249–58.
   PubMed Web of Science ®Google Scholar
• Ribeiro AC, Klingler PJ, Hinder RA, DeVault K. Esophageal manometry: a comparison of findings in younger and older patients. Am J Gastroenterol 1998;93:706–10.
   PubMedGoogle Scholar
• Schmucker DL. Aging and drug disposition: an update. Phar- macol Rev 1985;37:133–48.
   PubMed Web of Science ®Google Scholar
• Annesley TM. Special considerations for geriatric therapeu- tic drug monitoring. Clin Chem 1989;35:1337–41.
   PubMed Web of Science ®Google Scholar
• Altman, DF. Changes in gastrointestinal, pancreatic, biliary, and hepatic function with aging. Gastroenterol Clin North Am 1990;19:227–34.
   Google Scholar
• Russell RM. Changes in gastrointestinal function attributed to aging. Am J Clin Nutr 1992;55(6, suppl):1203–7S.
   Google Scholar
• Pilotto A, Franceschi M, Del Favero G, Fabrello R, Di Mario F, Valerio G. The effect of aging on oro-cecal transit time in normal subjects and patients with gallstone disease. Aging (Milano) 1995;7:234–7.
   Google Scholar
• Trey G, Marks IN, Louw JA, Jaskiewicz K, Sipponen P, Novis BH, et al. Changes in acid secretion over the years: a 30-year longitudinal study. J Clin Gastroenterol 1997;25:499–502.
   PubMedGoogle Scholar
• Holt PR, Balint JA. Effects of aging on intestinal lipid ab- sorption. Am J Physiol 1993;264:G1–6.
   PubMedGoogle Scholar
• Forbes GB, Reina JC. Adult lean body mass declines with age: some longitudinal observations. Metabolism 1970;19:653–63.
   PubMed Web of Science ®Google Scholar
• Novak LP. Aging, total body potassium, fat-free mass, and cell mass in males and females between ages 18 and 85 years. J Gerontol 1972;27:438–43.
   PubMedGoogle Scholar
• Borkan GA, Hults DE, Gerzof SG, Robbins AH, Silbert CK. Age changes in body composition revealed by computed to- mography. J Gerontol 1983;38:673–7.
   PubMedGoogle Scholar
• Kleine TO, Hackler R. Age-related changes in the blood- brain barrier of humans. Neurobiol Aging 1994;15:763–4.
   Google Scholar
• Kalaria RN. Cerebral vessels in ageing and Alzheimer’s dis- ease. Pharmacol Ther 1996;72:193–214.
   PubMed Web of Science ®Google Scholar
• Shah GN, Mooradian AD. Age-related changes in the blood- brain barrier. Exp Gerontol 1997;32:501–19.
   PubMed Web of Science ®Google Scholar
• Skoog I, Wallin A, Fredman P, Hesse C, Aevarsson O, Karls- son I, et al. A population study on blood-brain barrier func- tion in 85-year-olds: relation to Alzheimer’s disease and vas- cular dementia. Neurology 1998;50:966–71.
   Google Scholar
• Loi CM, Vestal RE. Drug metabolism in the elderly. Pharma- col Ther 1988;36:131–49.
   Google Scholar
• Greenblatt DJ. Reduced serum albumin concentration in the elderly: a report from the Boston Collaborative Drug Surveil- lance Program. J Am Geriatr Soc 1979;27:20–2.
   Google Scholar
• Adir J, Miller AK, Vestal RE. Effects of total plasma concen- tration and age on tolbutamide plasma protein binding. Clin Pharmacol Ther 1982;31:488–93.
   PubMedGoogle Scholar
• Abernethy DR, Kerzner L. Age effects on alpha-1-acid glyco- protein concentration and imipramine plasma protein bind- ing. J Am Geriatr Soc 1984;32:705–8.
   PubMed Web of Science ®Google Scholar
• Amitai Y, Kennedy EJ, DeSandre P, Frischer H. Distribution of amitriptyline and nortriptyline in blood: role of a1- glycoprotein. Ther Drug Monit 1993;15:267–73.
   Google Scholar
• Von Moltke LL, Abernethy DR, Greenblatt DJ. Kinetics and dynamics of psychotropic drugs in the elderly. In: Salzman C, ed. Clinical geriatric psychopharmacology. 3rd ed. Baltimore: Williams & Wilkins, 1998:70–93.
   Google Scholar
• Woodhouse KW, James OFW. Hepatic drug metabolism and ageing. Br Med Bull 1990;46:22–35.
   Google Scholar
• Yuen GJ. Altered pharmacokinetics in the elderly. Clin Geri- atr Med 1990;6:257–67.
   PubMedGoogle Scholar
• Le Couteur DG, McLean AJ. The aging liver: drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmaco- kinet 1998;34:359–73.
   PubMed Web of Science ®Google Scholar
• Schmucker DL, Woodhouse KW, Wang RK, Wynne H, James OF, McManus M, et al. Effects of age and gender on in vitro properties of human liver microsomal monooxygenases. Clin Pharmacol Ther 1990;48:365–74.
   Google Scholar
• Hunt CM, Westerkam WR, Stave GM, Wilson JAP. Hepatic cytochrome P-4503A (CYP3A) activity in the elderly. Mech Ageing Dev 1992;64;189–99.
   Google Scholar
• Pollock BG, Perel JM, Altieri LP, Kirshner M, Fasiczka AL, Houck PR, et al. Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology. Psychopharmacol Bull 1992; 28:163–8.
   Google Scholar
• Pollock BG. Recent developments in drug metabolism of rele- vance to psychiatrists. Harvard Rev Psychiatry 1994;2:204–13.
   PubMed Web of Science ®Google Scholar
• Gelenberg AJ. The P450 family. Biol Ther Psychiatry Newsl 1995;18:29–31.
   Google Scholar
• Nemeroff CB, Devane CL, Pollack BG. Summary and review of antidepressants and the cytochrome P450 system. Am Soc Clin Psychopharmacol Progress Notes 1995–96;6(4):38–40.
   Google Scholar
• Nemeroff CB, DeVane CL, Pollock BG. Newer antidepres- sants and the cytochrome P450 system. Am J Psychiatry 1996;153:311–20.
   PubMed Web of Science ®Google Scholar
• Michalets EL. Update: clinically significant cytochrome P- 450 drug interactions. Pharmacotherapy 1998;18:84–112.
   PubMed Web of Science ®Google Scholar
• Patel J, Salzman C. Enzyme metabolism and drug inter- action. In: Salzman C, ed. Clinical geriatric psychopharma- cology. 3rd ed. Baltimore: Williams & Wilkins, 1998: 547–52.
   Google Scholar
• Anonymous. Reference guide to substrates, inhibitors and in- ducers of the major human liver cytochrome P450 enzymes involved in xenobiotic transformation. Research Triangle Park, North Carolina: Intek Labs, 1999.
   Google Scholar
• Anonymous. Micromedex computer and clinical information system, vol 99. Englewood, Colorado: Micromedex, 1999.
   Google Scholar
• Schmucker DL. Age-related changes in drug disposition. Pharmacol Rev 1978;30:445–56.
   Google Scholar
• Pearson MW, Roberts CJC. Drug induction of hepatic en- zymes in the elderly. Age Ageing 1984;13:313–6.
   Google Scholar
• Vestal RE. Aging and determinants of hepatic drug clear- ance. Hepatology 1989;9:331–4.
   PubMedGoogle Scholar
• Zubenko GS. Molecular neurobiology of Alzheimer’s disease (syndrome?). Harvard Rev Psychiatry 1997;5:177–213.
   Web of Science ®Google Scholar
• Baum C, Kennedy DL, Knapp DE, Faich GA. Drug utiliza- tion in the US: 1985. Seventh Annual Review, Food and Drug Administration, Center for Drugs and Biologics, Rockville, Maryland, 1986.
   Google Scholar
• Balter MB, Levine J, Manheimer DI. Cross-national study of the extent of anti-anxiety sedative drug use. N Engl J Med 1974;290:769–74.
   PubMed Web of Science ®Google Scholar
• Boston Collaborative Drug Surveillance Program. Clinical depression of the central nervous system due to diazepam and chlordiazepoxide in relation to cigarette smoking and age. N Engl J Med 1973;288:277–80.
   Google Scholar
• Castleden CM, George CF, Marcer D, Hallett C. Increased sensitivity to nitrazepam in old age. BMJ 1977;1:10–2.
   PubMed Web of Science ®Google Scholar
• Giles HG, MacLeod SM, Wright JR, Sellers EM. Influence of age and previous use on diazepam dosage required for endos- copy. Can Med Assoc J 1978;118:513–4.
   PubMed Web of Science ®Google Scholar
• Reidenberg MM, Levy M, Warner H, Coutinho CB, SchwartzMA, Yu G, et al. Relationship between diazepam dose, plasma level, age, and central nervous system depression. Clin Pharmacol Ther 1978;23:371–4.
   PubMed Web of Science ®Google Scholar
• Thompson TL II, Moran MG, Nies AS. Psychotropic drug use in the elderly: part 1. N Engl J Med 1983;308:134–8.
   Google Scholar
• Thompson TL II, Moran MG, Nies AS. Psychotropic drug use in the elderly: part 2. N Engl J Med 1983;308:194–9.
   Google Scholar
• Cook PJ, Flanagan R, James IM. Diazepam tolerance: effect of age, regular sedation, and alcohol. BMJ 1984;289:351–3.
   PubMed Web of Science ®Google Scholar
• Pomara N, Stanley B, Block R, Guido J, Russ D, Berchou R, et al. Adverse effects of single therapeutic doses of diazepam on performance in normal geriatric subjects: relationship to plasma concentrations. Psychopharmacology 1984;84:342–6.
   PubMed Web of Science ®Google Scholar
• Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA 1989;262:3303–7.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharma- cokinetics of anxiolytics and hypnotics in the elderly: thera- peutic considerations (part II). Clin Pharmacokinet 1991; 21:262–73.
   PubMed Web of Science ®Google Scholar
• Kroboth PD, McAuley JW, Smith RB. Alprazolam in the el- derly: pharmacokinetics and pharmacodynamics during mul- tiple dosing. Psychopharmacology 1990;100:477–84.
   Google Scholar
• Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharma- cokinetics of anxiolytics and hypnotics in the elderly: thera- peutic considerations (part I). Clin Pharmacokinet 1991;21:165–77.
   PubMed Web of Science ®Google Scholar
• Herings RMC, Stricker BH, De Boer A, Bakker A, Sturmans F. Benzodiazepines and the risk of falling leading to femur fractures: dosage more important than elimination half-life. Arch Intern Med 1995;155:1801–7.
   PubMed Web of Science ®Google Scholar
• Pomara N, Stanley B, Block R, Berchou RC, Stanley M, Greenblatt DJ, et al. Increased sensitivity of the elderly to the central depressant effects of diazepam. J Clin Psychiatry 1985;46:185–7.
   PubMed Web of Science ®Google Scholar
• Swift CG, Ewen JM, Clarke P, Stevenson IH. Responsiveness to oral diazepam in the elderly: relationship to total and free plasma concentrations. Br J Clin Pharmacol 1985;20:111–8.
   Google Scholar
• Nikaido AM, Ellinwood EH Jr, Heatherly DG, Gupta SK. Age-related increase in CNS sensitivity to benzodiazepines as assessed by task difficulty. Psychopharmacology 1990; 100:90–7.
   PubMed Web of Science ®Google Scholar
• Bertz RJ, Kroboth PD, Kroboth FJ, Reynolds IJ, Salek F, Wright CE, et al. Alprazolam in young and elderly men: sen- sitivity and tolerance to psychomotor, sedative and memory effects. J Pharmacol Exp Ther 1997;281:1317–29.
   Google Scholar
• Allen SJ, Benton JS, Goodhardt MJ, Haan EA, Sims NR, Smith CC, et al. Biochemical evidence of selective nerve cell changes in the normal ageing human and rat brain. J Neuro- chem 1983;41:256–65.
   PubMed Web of Science ®Google Scholar
• McGeer EG. Neurotransmitter system in aging and senile dementia. Prog Neuropsychopharmacol 1981;5:435–45.
   Google Scholar
• Bareggi SR, Franceschi M, Smirne S. Neurochemical find- ings in cerebrospinal fluid in Alzheimer’s disease. In: Gott- fries CG, ed. Normal aging, Alzheimer’s disease, and senile dementia: aspects of etiology, pathogenesis, diagnosis, and treatment. Brussels: E´ ditions de l’Universite´ de Bruxelles, 1985:203–12.
   Google Scholar
• Hare TA, Wood JH, Manyam BV, Gerner RH, Ballenger JC, Post RM. Central nervous system)’-aminobutyric acid activ- ity in man; relationship to age and sex as reflected in CSF. Arch Neurol 1982;39:247–9.
   Google Scholar
• Satlin A, Liptzin B. Diagnosis and treatment of mania. In: Salzman C, ed. Clinical geriatric psychopharmacology. 3rd ed. Baltimore: Williams & Wilkins, 1998:310–30.
   Google Scholar
• Tune L, Carr S, Hoag E, Cooper T. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am J Psychiatry 1992;149:1393–4.
   PubMed Web of Science ®Google Scholar
• Molchan SE, Martinez RA, Hill JL, Weingartner HJ, Thomp- son K, Vitiello B, et al. Increased cognitive sensitivity to sco- polamine with age and a perspective on the scopolamine model. Brain Res Brain Res Rev 1992;17:215–26.
   PubMedGoogle Scholar
• Lee KS, Frey KA, Koeppe RA, Buck A, Mulholland GK, Kuhl DE. In vivo quantification of cerebral muscarinic receptors in normal human aging using positron emission tomography and [11C]tropanyl benzilate. J Cereb Blood Flow Metab 1996; 16:303–10.
   Google Scholar
• Suhara T, Inoue O, Kobayashi K, Suzuki K, Tateno Y. Age- related changes in human muscarinic acetylcholine receptors measured by positron emission tomography. Neurosci Lett 1993;149:225–8.
   PubMedGoogle Scholar
• Nordberg A, Alafuzoff I, Winblad B. Nicotinic and muscarinic subtypes in the human brain: changes with aging and de- mentia. J Neurosci Res 1992;31:103–11.
   PubMed Web of Science ®Google Scholar
• Flynn DD, Mash DC. Characterization of L-[3H]nicotine binding in human cerebral cortex: comparison between Alz- heimer’s disease and the normal. J Neurochem 1986;47:1948–54.
   PubMed Web of Science ®Google Scholar
• Cutler R, Joseph JA, Yamagami K, Villalobos-Molina R, Roth GS. Area specific alterations in muscarinic stimulated low Km GTPase activity in aging and Alzheimer’s disease: impli- cations for altered signal transduction. Brain Res 1994;664:54–60.
   PubMed Web of Science ®Google Scholar
• Jorm AF, Korten AE, Henderson AS. The prevalence of de- mentia: a quantitative integration of the literature. Acta Psychiatr Scand 1987;76:465–79.
   PubMed Web of Science ®Google Scholar
• Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, Chown MJ, et al. Prevalence of Alzheimer’s disease in a community population of older persons: higher than pre- viously reported. JAMA 1989;262:2551–6.
   PubMed Web of Science ®Google Scholar
• Bachman DL, Wolf PA, Linn R, Knoefel JE, Cobb J, Belanger A, et al. Prevalence of dementia and probable senile demen- tia of the Alzheimer type in the Framingham Study. Neurol- ogy 1992;42:115–9.
   PubMed Web of Science ®Google Scholar
• Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, DeLong MR. Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain. Science 1982;215:1237–9.
   PubMed Web of Science ®Google Scholar
• Arendt T, Bigl V, Arendt A, Tennstedt A. Loss of neurons in the nucleus basalis of Meynert in Alzheimer’s disease, paral- ysis agitans, and Korsakoff ’s disease. Acta Neuropathol (Berl) 1983;61:101–8.
   PubMed Web of Science ®Google Scholar
• Saper CB, German DC, White CL III. Neuronal patholog in the nucleus basalis and associated cell groups in senile dementia of the Alzheimer’s type: possible role in cell loss. Neurology 1985;35:1089–95.
   PubMed Web of Science ®Google Scholar
• Pope A, Hess HH, Lewin E. Microchemical pathology of the cerebral cortex in pre-senile dementias. Trans Am Neurol Assoc 1964;89:15–6.
   Google Scholar
• Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer’s disease [Letter]. Lancet 1976;2:1403.
   PubMed Web of Science ®Google Scholar
• Rossor MN, Garrett NJ, Johnson AL, Mountjoy CQ, Roth M, Iversen LL. A post-mortem study of the cholinergic and GABA systems in senile dementia. Brain 1982;105:313–30.
   PubMed Web of Science ®Google Scholar
• Bird TD, Stranahan S, Sumi SM, Raskind M. Alzheimer’s disease: choline acetyltransferase activity in brain tissue from clinical and pathological subgroups. Ann Neurol 1983; 14:284–93.
   PubMed Web of Science ®Google Scholar
• Bowen DM, Allen SJ, Benton JS, Goodhardt MJ, Haan EA, Palmer AM, et al. Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzhei- mer’s disease. J Neurochem 1983;41:266–72.
   PubMed Web of Science ®Google Scholar
• Sims NR, Bowen DM, Allen SJ, Smith CCT, Neary D, Thomas DJ, et al. Presynaptic cholinergic dysfunction in pa- tients with dementia. J Neurochem 1983;40:503–9.
   PubMed Web of Science ®Google Scholar
• Drachman DA, Leavitt J. Human memory and the choliner- gic system: a relationship to aging? Arch Neurol 1974;30:113–21.
   PubMed Web of Science ®Google Scholar
• Bartus RT, Dean RL III, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217:408–14.
   PubMed Web of Science ®Google Scholar
• Greenamyre JT, Maragos WF. Neurotransmitter receptors in Alzheimer disease. Cerebrovasc Brain Metab Rev 1993;5:61–94.
   PubMedGoogle Scholar
• Smith CJ, Perry EK, Perry RH, Fairbairn AF, Birdsall NJM. Guanine nucleotide modulation of muscarinic cholinergic re- ceptor binding in postmortem human brain—a preliminary study in Alzheimer’s disease. Neurosci Lett 1987;82:227–32.
   Google Scholar
• Flynn DD, Weinstein DA, Mash DC. Loss of high-affinity ag- onist binding to M1 muscarinic receptors in Alzheimer’s dis- ease: implications for the failure of cholinergic replacement therapies. Ann Neurol 1991;29:256–62.
   PubMed Web of Science ®Google Scholar
• Sunderland T, Esposito G, Molchan SE, Coppola R, Jones DW, Gorey J, et al. Differential cholinergic regulation in Alz- heimer’s patients compared to controls following chronic blockade with scopolamine: a SPECT study. Psychopharma- cology 1995;121:231–41.
   Google Scholar
• Flynn DD, Mash DC. Characterization of L-[3H]nicotine bind- ing in human cerebral cortex: comparison between Alzhei- mer’s disease and the normal. J Neurochem 1986;47:1948–54.
   PubMed Web of Science ®Google Scholar
• Shimohama S, Taniguchi T, Fujiwara M, Kameyama M. Changes in nicotinic and muscarinic cholinergic receptors in Alzheimer-type dementia. J Neurochem 1986;46:288–93.
   PubMed Web of Science ®Google Scholar
• Whitehouse PJ, Martino AM, Antuono PG, Lowenstein PR, Coyle JT, Price DL, et al. Nicotinic acetylcholine binding sites in Alzheimer’s disease. Brain Res 1986;371:146–51.
   PubMed Web of Science ®Google Scholar
• Perry EK, Perry RH, Smith CJ, Dick DJ, Candy JM, Edward- son JA, et al. Nicotinic receptor abnormalities in Alzheimer’s and Parkinson’s diseases. J Neurol Neurosurg Psychiatry 1987;50:806–9.
   PubMed Web of Science ®Google Scholar
• Araujo DM, Lapchak PA, Robitaille Y, Gauthier S, Quirion R. Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzhei- mer’s disease. J Neurochem 1988;50:1914–23.
   Google Scholar
• Rinne JO, Myllykyla¨ P, Lo¨nnberg P, Marjama¨ ki P. A postmor- tem study of brain nicotinic receptors in Parkinson’s and Alz- heimer’s disease. Brain Res 1991;547:167–70.
   Google Scholar
• Hansen L, Salmon D, Galasko D, Masliah E, Katzman R, DeTeresa R, et al. The Lewy body variant of Alzheimer’s dis- ease: a clinical and pathologic entity. Neurology 1990;40:1–8.
   PubMed Web of Science ®Google Scholar
• Lippa CF, Smith TW, Swearer JM. Alzheimer’s disease and Lewy body disease: a comparative clinicopathological study. Ann Neurol 1994;35:81–8.
   PubMed Web of Science ®Google Scholar
• Perry EK, Marshall E, Perry RH, Irving D, Smith CJ, Blessed G, et al. Cholinergic and dopaminergic activities in senile dementia of Lewy body type. Alzheimer Dis Assoc Dis- ord 1990;4:87–95.
   PubMedGoogle Scholar
• Perry EK, McKeith I, Thompson P, Marshall E, Kerwin J, Jabeen S, et al. Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Par- kinson’s disease, and Alzheimer’s disease. Ann NY Acad Sci 1991;640:197–202.
   PubMed Web of Science ®Google Scholar
• Perry EK, Irving D, Kerwin JM, McKeith IG, Thompson P, Collerton D, et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson’s and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord 1993;7:69–79.
   PubMed Web of Science ®Google Scholar
• Fo¨rstl H, Burns A, Luthert P, Cairns N, Levy R. The Lewy- body variant of Alzheimer’s disease: clinical and pathological findings. Br J Psychiatry 1993;162:385–92.
   PubMed Web of Science ®Google Scholar
• Langlais PJ, Thal L, Hansen L, Galasko D, Alford M, Mas- liah E. Neurotransmitters in basal ganglia and cortex of Alz- heimer’s disease with and without Lewy bodies. Neurology 1993;43:1927–34.
   Google Scholar
• Kalish SC, Bohn RL, Mogun H, Glynn RJ, Gurwitz JH, Avorn J. Antipsychotic prescribing patterns and the treatment of extrapyramidal symptoms in older people. J Am Geriatr Soc 1995;43:967–73.
   Google Scholar
• Sweet RA, Mulsant BH, Gupta B, Rifai AH, Pasternak RE, McEachran A, et al. Duration of neuroleptic treatment and prevalence of tardive dyskinesia in late life. Arch Gen Psychi- atry 1995;52:478–86.
   PubMed Web of Science ®Google Scholar
• Hartikainen P, Soininen H, Reinikainen KJ, Sirvio¨ J, Soik- keli R, Riekkinen PJ. Neurotransmitter markers in the cere- brospinal fluid of normal subjects: effects of aging and other confounding factors. J Neural Transm Gen Sect 1991;84:103–17.
   Google Scholar
• Zubenko GS, Moossy J, Kopp U. Neurochemical correlates of major depression in primary dementia. Arch Neurol 1990; 47:209–14.
   PubMedGoogle Scholar
• Zubenko GS, Moossy J. Major depression in primary demen- tia: clinical and neuropathologic correlates. Arch Neurol 1988;45:1182–6.
   PubMedGoogle Scholar
• Zubenko GS, Moossy J, Martinez AJ, Rao G, Claassen D, Ro- sen J, et al. Neuropathological and neurochemical correlates of psychosis in primary dementia. Arch Neurol 1991;48:619–24.
   Google Scholar
• Zubenko GS. Clinicopathological and neurochemical corre- lates of major depression and psychosis in primary dementia. Int Psychogeriatr 1996;8(suppl 3):219–23.
   Google Scholar
• Meek JL, Bertilsson L, Cheney DL, Zsilla G, Costa E. Aging- induced changes in acetylcholine and serotonin content of discrete brain nuclei. J Gerontol 1977;32:129–31.
   Google Scholar
• Patel A, Maloney A, Damato AN. On the frequency and re- producibility of orthostatic blood pressure changes in healthy community-dwelling elderly during 60-degree head-up tilt. Am Heart J 1993;126:184–8.
   Google Scholar
• Mets TF. Drug-induced orthostatic hypotension in older pa- tients. Drugs Aging 1995;6:219–28.
   PubMed Web of Science ®Google Scholar
• Verhaeverbeke I, Mets T. Drug-induced orthostatic hypo- tension in the elderly: avoiding its onset. Drug Saf 1997;17:105–18.
   PubMed Web of Science ®Google Scholar
• Abernethy DR. Altered pharmacodynamics of cardiovascular drugs and their relation to altered pharmacokinetics in el- derly patients. Clin Geriatr Med 1990;6:285–92.
   Google Scholar
• Feely J, Coakley D. Altered pharmacodynamics in the el- derly. Clin Geriatr Med 1990;6:269–83.
   PubMedGoogle Scholar
• Ha¨ mmerlein A, Derendorf H, Lowenthal DT. Pharmocoki- netic and pharmacodynamic changes in the elderly: clinical implications. Clin Pharmacokinet 1998;35:49–64.
   Google Scholar
• Cumming RG. Epidemiology of medication-related falls and fractures in the elderly. Drugs Aging 1998;12:43–53.
   PubMed Web of Science ®Google Scholar
• Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med 1988;319:1701–7.
   PubMed Web of Science ®Google Scholar
• Campbell AJ, Borrie MJ, Spears GF. Risk factors for falls in a community-based prospective study of people 70 years and older. J Gerontol Med Sci 1989;44:M112–7.
   Google Scholar
• Campbell AJ, Borrie MJ, Spears GF, Jackson SL, Brown JS, Fitzgerald JL. Circumstances and consequences of falls expe- rienced by a community population 70 years and over during a prospective study. Age Ageing 1990;19:136–41.
   PubMed Web of Science ®Google Scholar
• Tinetti ME, Speechley M. Prevention of falls among the el- derly. N Engl J Med 1989;320:1055–9.
   PubMed Web of Science ®Google Scholar
• Cummings SR, Kelsey JL, Nevitt MC, O’Dowd KJ. Epidemi- ology of osteoporosis and osteoporotic fractures. Epidemiol Rev 1985;7:178–208.
   PubMed Web of Science ®Google Scholar
• Katelaris AG, Cumming RG. Health status before and mor- tality after hip fracture. Am J Public Health 1996;86:557–60.
   PubMed Web of Science ®Google Scholar
• Cumming RG, Klineberg R, Katelaris A. Cohort study of risk of institutionalisation after hip fracture. Aust NZ J Public Health 1996;20:579–82.
   PubMed Web of Science ®Google Scholar
• Ray WA, Griffin MR, Schaffner W, Baugh DK, Melton LJ III. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987;316:363–9.
   PubMed Web of Science ®Google Scholar
• Ray WA, Griffin MR, Malcolm E. Cyclic antidepressants and the risk of hip fracture. Arch Intern Med 1991;151:754–6.
   PubMedGoogle Scholar
• Lipsitz LA, Jonsson PV, Kelley MM, Koestner JS. Causes and correlates of recurrent falls in ambulatory frail elderly. J Gerontol Med Sci 1991;46:M114–22.
   Google Scholar
• Ruthazer R, Lipsitz LA. Antidepressants and falls among el- derly people in long-term care. Am J Public Health 1993;83:746–9.
   PubMed Web of Science ®Google Scholar
• Sorock GS, Shimkin EE. Benzodiazepine sedatives and the risk of falling in a community dwelling elderly cohort. Arch Intern Med 1988;148:2441–4.
   Google Scholar
• Cumming RG, Miller JP, Kelsey JL, Davis P, Arfken CL, Birge SJ, et al. Medications and multiple falls in elderly people: the St. Louis OASIS study. Age Ageing 1991;20:455–61.
   PubMed Web of Science ®Google Scholar
• Aisen PS, Deluca T, Lawlor BA. Falls among geropsychiatry inpatients are associated with PRN medications for agita- tion. Int J Geriatr Psychiatry 1992;7:709–12.
   Web of Science ®Google Scholar
• Cumming RG, Klineberg RJ. Psychotropics, thiazide diuret- ics and hip fractures in the elderly. Med J Aust 1993;158:414–7.
   PubMed Web of Science ®Google Scholar
• Ryyna¨ nen OP, Kivela¨ SL, Honkanen R, Laippala P, Saano V. Medications and chronic diseases as risk factors for falling injuries in the elderly. Scand J Soc Med 1993;21:264–71.
   Google Scholar
• Yip YB, Cumming RG. The association between medications and falls in Australian nursing-home residents. Med J Aust 1994;160:14–8.
   PubMed Web of Science ®Google Scholar
• Gales BJ, Menard SM. Relationship between the administra- tion of selected medications and falls in hospitalized elderly patients. Ann Pharmacother 1995;29:354–8.
   Google Scholar
• Lord SR, Anstey KJ, Williams P, Ward JA. Psychoactive med- ication use, sensori-motor function and falls in older women. Br J Clin Pharmacol 1995;39:227–34.
   Google Scholar
• Luukinen H, Koski K, Laippala P, Kivela¨ SL. Predictors for recurrent falls among the home-dwelling elderly. Scand J Prim Health Care 1995;13:294–9.
   PubMed Web of Science ®Google Scholar
• Prudham D, Evans JG. Factors associated with falls in the elderly: a community study. Age Ageing 1981;10:141–6.
   PubMedGoogle Scholar
• Sorock GS. A case-control study of falling incidents among the hospitalized elderly. J Saf Res 1983;14:47–52.
   Google Scholar
• Mion LC, Gregor S, Buettner M, Chwirchak D, Lee O, Paras W. Falls in the rehabilitation setting: incidence and charac- teristics. Rehab Nurs 1989;14:17–22.
   Google Scholar
• Wells BG, Middleton B, Lawrence G, Lillard D, Safarik J. Factors associated with the elderly falling in intermediate care facilities. Drug Intell Clin Pharm 1985;19:142–5.
   Google Scholar
• Lord SR, Sambrook PN, Gilbert C, Kelly PJ, Nguyen T, Web- ster IW, et al. Postural stability, falls and fractures in the elderly: results from the Dubbo Osteoporosis Epidemiology Study. Med J Aust 1994; 160:684–5, 688–91.
   Google Scholar
• Ensrud KE, Nevitt MC, Yunis C, Hulley SB, Grimm RH, Cummings SR. Postural hypotension and postural dizziness in elderly women: the study of osteoporotic fractures. Arch Intern Med 1992;152:1058–64.
   PubMed Web of Science ®Google Scholar
• Koski K, Luukinen H, Laippala P, Kivela¨ SL. Physiological factors and medications as predictors of injurious falls by el- derly people: a prospective population-based study. Age Age- ing 1996;25:29–38.
   PubMed Web of Science ®Google Scholar
• Middler S, Pak CY, Murad F, Bartter FC. Thiazide diuretics and calcium metabolism. Metabolism 1973;22:139–46.
   PubMed Web of Science ®Google Scholar
• Jones G, Nguyen T, Sambrook PN, Eisman JA. Thiazide di- uretics and fractures: can meta-analysis help? J Bone Miner Res 1995;10:106–11.
   Web of Science ®Google Scholar
• Lipsitz LA, Jonsson PV, Kelley MM, Koestner JS. Causes and correlates of recurrent falls in ambulatory frail elderly. J Gerontol Med Sci 1991;46:M114–22.
   Google Scholar
• Myers AH, Baker SP, Van Natta ML, Abbey H, Robinson EG. Risk factors associated with falls and injuries among elderly institutionalized persons. Am J Epidemiol 1991;133:1179–90.
   PubMed Web of Science ®Google Scholar
• Hoppmann RA, Peden JG, Ober SK. Central nervous system side effects of nonsteroidal anti-inflammatory drugs: aseptic meningitis, psychosis, and cognitive dysfunction. Arch Intern Med 1991;151:1309–13.
   PubMed Web of Science ®Google Scholar
• Bauer DC, Orwoll ES, Fox KM, Vogt TM, Lane NE, Hochberg MC, et al. Aspirin and NSAID use in older women: effect on bone mineral density and fracture risk. J Bone Miner Res 1996;11:29–35.
   Google Scholar
• Shorr RI, Griffin MR, Daugherty JR, Ray WA. Opioid analge- sics and the risk of hip fracture in the elderly: codeine and propoxyphene. J Gerontol Med Sci 1992;47:M111–5.
   Google Scholar
• Robbins AS, Rubenstein LZ, Josephson KR, Schulman BL, Osterweil D, Fine G. Predictors of falls among elderly people: results of two population-based studies. Arch Intern Med 1989;149:1628–33.
   PubMed Web of Science ®Google Scholar
• Thapa PB, Gideon P, Fought RL, Ray WA. Psychotropic drugs and risk of recurrent falls in ambulatory nursing home residents. Am J Epidemiol 1995;142:202–11.
   PubMed Web of Science ®Google Scholar
• Cooper JK, Love DW, Raffoul PR. Intentional prescription nonadherence (noncompliance) by the elderly. J Am Geriatr Soc 1982;30:329–33.
   PubMed Web of Science ®Google Scholar
• Ostrom JR, Hammarlund ER, Christensen DB, Plein JB, Kethley AJ. Medication usage in an elderly population. Med Care 1985;23:157–64.
   PubMed Web of Science ®Google Scholar
• Jackson JE, Ramsdell JW, Renvall M, Swart J, Ward H. Re- liability of drug histories in a specialized geriatric outpatient clinic. J Gen Intern Med 1989;4:39–43.
   PubMedGoogle Scholar
• Lamy PP, Salzman C, Nevis-Olesen J. Drug prescribing pat- terns, risks, and compliance guidelines. In: Salzman C, ed. Clinical geriatric psychopharmacology. 2nd ed. Baltimore: Williams & Wilkins, 1992:15–37.
   Google Scholar
• Lamy PP. Compliance in long-term care. Geriatr Med Today 1986;5:61–75.
   Google Scholar
• Col N, Fanale JE, Kronholm P. The role of medication non- compliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med 1990;150:841–5.
   PubMed Web of Science ®Google Scholar
• Mesulam MM, Mufson EJ, Rogers J. Age-related shrinkage of cortically projecting cholinergic neurons: a selective effect. Ann Neurol 1987;22:31–36.
   Google Scholar
• Cohen BM, Renshaw PF, Stoll AL, Wurtman RJ, Yurgelun- Todd D, Babb SM. Decreased brain choline uptake in older adults: an in vitro proton magnetic resonance spectroscopy study. JAMA 1995;274:902–7.
   PubMed Web of Science ®Google Scholar
• Court JA, Perry EK, Johnson M, Piggott MA, Kerwin JA, Perry RH, et al. Regional patterns of cholinergic and gluta- mate activity in the developing and aging human brain. Brain Res Dev Brain Res 1993;74:73–82.
   PubMedGoogle Scholar
• Allen SJ, Benton JS, Goodhardt MJ, Haan EA, Sims NR, Smith CC, et al. Biochemical evidence of selective nerve cell changes in the normal ageing human and rat brain. J Neuro- chem 1983;41:256–65.
   PubMed Web of Science ®Google Scholar
• Nakano S, Kato T, Nakamura S, Kameyama M. Acetylcholin- esterase activity in cerebrospinal fluid of patients with Alz- heimer’s disease and senile dementia. J Neurol Sci 1986;75:213–23.
   Google Scholar
• Morgan DG, May PC, Finch CE. Dopamine and serotonin systems in human and rodent brain: effects of age and neuro- degenerative disease. J Am Geriatr Soc 1987;35:334–45.
   Google Scholar
• McGeer EG. Neurotransmitter systems in aging and senile dementia. Prog Neuropsychopharmacol 1981;5:435–45.
   Google Scholar
• Robinson DS, Sourkes TL, Nies A, Harris LS, Spector S, Bartlett DL, et al. Monoamine metabolism in human brain. Arch Gen Psychiatry 1977;34:89–92.
   PubMed Web of Science ®Google Scholar
• Oreland L, Gottfries CG. Brain and brain monoamine oxi- dase in aging and in dementia of Alzheimer’s type. Prog Neu- ropsychopharmacol Biol Psychiatry 1986;10:533–40.
   Google Scholar
• De Keyser J, Ebinger G, Vauquelin G. Age-related changes in the human nigrostriatal dopaminergic system. Ann Neurol 1990;27:157–161.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang GJ, Fowler JS, Ding YS, Gur RC, Gatley J, et al. Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging. Ann Neurol 1998;44:143–7.
   PubMed Web of Science ®Google Scholar
• Rinne JO, Heitala J, Ruotsalainen U, Sa¨ ko¨ E, Laihinen A, Na° gren K, et al. Decrease in human striatal dopamine D2 receptor density with age: a PET study with [11C] raclopride. J Cereb Blood Flow Metab 1993;13:310–4.
   Google Scholar
• Wang GJ, Volkow ND, Logan J, Fowler JS, Schlyer D, Mac- Gregor RR, et al. Evaluation of age-related changes in seroto- nin 5-HT2 and dopamine D2 receptor availability in healthy human subjects. Life Sci 1995;56:PL249–53.
   PubMed Web of Science ®Google Scholar
• Roth GS, Joseph JA. Age-related changes in the transcrip- tional and posttranscriptional regulation of the dopaminer- gic system. Life Sci 1994;55:2031–5.
   Google Scholar
• Van Dyck CH, Seibyl JP, Malison RT, Laruelle M, Wallace E, Zoghbi SS, et al. Age-related decline in striatal dopamine transporter binding with iodine-123-beta-CIT SPECT. J Nucl Med 1995;36:1175–81.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Fowler JS, Wang GJ, Logan J, Schlyer D, Mac- Gregor R, et al. Decreased dopamine transporters with age in healthy human subjects. Ann Neurol 1994;36:237–9.
   Google Scholar
• Bannon MJ, Poosch MS, Xia Y, Goebel DJ, Cassin B, Kas- patos G. Dopamine transporter mRNA content in human substantia nigra decreases precipitously with age. Proc Natl Acad Sci USA 1992;89:7095–9.
   Google Scholar
• Mann DMA. Is the pattern of nerve cell loss in aging and Alzheimer’s disease a real, or only an apparent, selectivity? Neurobiol Aging 1991;12:340–3.
   Google Scholar
• Sastre M, Garc´ıa-Sevilla JA. Density of alpha-2A adrenocep- tors and Gi proteins in the human brain: ratio of high-affinity agonist sites to antagonist sites and effect of age. J Pharma- col Exp Ther 1994;269:1062–72.
   PubMed Web of Science ®Google Scholar
• Supiano MA, Hogikyan RV. High affinity platelet a2- adrenergic receptor density is decreased in older humans. J Gerontol Biol Sci 1993;48:B173–9.
   Google Scholar
• Pascual J, Del Arco C, Gonza´ lez AM, Pazos A. Quantitative light microscopic autoradiographic localization of a2- adrenoceptors in the human brain. Brain Res 1992;585:116–27.
   Google Scholar
• Kalaria RN, Andorn AC. Adrenergic receptors in aging and Alzheimer’s disease: decreased alpha 2-receptors demon- strated by [3H]p-aminoclonidine binding in prefrontal cortex. Neurobiol Aging 1991;12:131–6.
   PubMed Web of Science ®Google Scholar
• Arango V, Ernsberger P, Marzuk PM, Chen JS, Tierney H, Stanley M, et al. Autoradiographic demonstration of in- creased serotonin 5-HT2 and f3-adrenergic receptor binding sites in the brain of suicide victims. Arch Gen Psychiatry 1990;47:1038–47.
   PubMed Web of Science ®Google Scholar
• Kalaria RN, Andorn AC, Tabaton M, Whitehouse PJ, Harik SI, Unnerstall JR. Adrenergic receptors in aging and Alzhei- mer’s disease: increased f32-receptors in prefrontal cortex and hippocampus. J Neurochem 1989;53:1772–81.
   Google Scholar
• Insel PA. Adrenergic receptors, G proteins, and cell regula- tion: implications for aging research. Exp Gerontol 1993;28:341–8.
   Google Scholar
• Gottfries CG. Neurochemical aspects of aging and diseases with cognitive impairment. J Neurosci Res 1990;27:541–7.
   PubMed Web of Science ®Google Scholar
• Marcusson J, Oreland L, Winblad B. Effect of age on human brain serotonin (S-1) binding sites. J Neurochem 1984;43:1699–705.
   PubMed Web of Science ®Google Scholar
• Burnet PWJ, Eastwood SL, Harrison PJ. Detection and quantification of 5-HT1A and 5-HT2A receptor mRNAs in hu- man hippocampus using a reverse transcriptase–polymerase chain reaction (RT-PCR) technique and their correlation with binding site densities and age. Neurosci Lett 1994;178:85–9.
   Google Scholar
• Marcusson JO, Alafuzoff I, Ba¨ ckstro¨m IT, Ericson E, Gott- fries CG, Winblad B. 5-Hydroxytryptamine–sensitive [3H]imi- pramine binding of protein nature in the human brain, II: Effect of normal aging and dementia disorders. Brain Res 1987;425:137–45.
   Google Scholar
• Middlemiss DN, Palmer AM, Edel N, Bowen DM. Binding of the novel serotonin agonist 8-hydroxy-2-(di-n-propylamino) tetralin in normal and Alzheimer brain. J Neurochem 1986; 46:993–6.
   Google Scholar
• Baeken C, D’haenen H, Flamen P, Mertens J, Terriere D, Chavatte K, et al. 123I-5-I-R91150, a new single-photon emis- sion tomography ligand for 5-HT2A receptors: influence of age and gender in healthy subjects. Eur J Nucl Med 1998;25:1617–22.
   Google Scholar
• Meltzer CC, Smith G, Price JC, Reynolds CF III, Mathis CA, Greer P, et al. Reduced binding of [18F]altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correction. Brain Res 1998;813:167–71.
   PubMed Web of Science ®Google Scholar
• Wang GJ, Volkow ND, Logan J, Fowler JS, Schlyer D, Mac- Gregor RR, et al. Evaluation of age-related changes in seroto- nin 5-HT2 and dopamine D2 receptor availability in healthy human subjects. Life Sci 1995;56:PL249–53.
   PubMed Web of Science ®Google Scholar
• Sparks DL. Aging and Alzheimer’s disease: altered cortical serotonergic binding. Arch Neurol 1989;46:138–40.
   Google Scholar